Stryker Expands Neuro Line With Synergetics Portfolio Buy
This article was originally published in The Gray Sheet
Stryker added to its neuro device mix with the acquisition of Synergetics USA's portfolio, leaving the firm's ophthalmic device line with Valeant Pharmaceuticals.
You may also be interested in...
Stryker Charges Up EMS Business With Billion-Dollar Buy Of Physio-Control
Automated external defibrillator firm Physio-Control will sit in Stryker's existing Emergency Medical Services business once the $1.28 billion acquisition is complete. The expanded division will be "the segment leader in EMS equipment,” Stryker says.
Stryker In Neverland: Firm Ups Focus On Averting Avoidable Events With Sage Acquisition
Stryker will pay nearly $2.8 billion to buy Sage Products and its portfolio of products to prevent health care "never events," which hospitals are increasingly motivated to avoid.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.